STOCK TITAN
  1. Home
  2. Sec-filings
  3. BBNX
  4. [Form 4] Beta Bionics, Inc. Insider Trading Activity

Beta Bionics (BBNX) CFO sells 4,413 shares under Rule 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Financial Officer Stephen Feider exercised employee stock options for 4,413 shares of common stock at an exercise price of $5.10 per share and sold 4,413 shares at a weighted average price of $17.014 on August 22, 2025, pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.

After these transactions, he directly holds 45,503 shares of common stock and employee stock options covering 99,695 shares, with the option grant vesting in 48 equal monthly installments measured from September 14, 2023.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine option exercise followed by structured sale under a 10b5-1 plan; ownership modestly reduced, proceeds realized near market.

The reporting CFO exercised an in-the-money option (exercise $5.10) and sold the resulting 4,413 shares under a pre-established Rule 10b5-1 plan at a weighted average of $17.014, realizing gross consideration roughly equal to $75,000 (before fees/taxes). This is a common liquidity event for insiders and is executed under an affirmative defense plan, reducing reported beneficial ownership by ~8.8% of prior holdings (49,916 to 45,503). No additional compensatory or irregular transactions are disclosed.

TL;DR: Transaction appears compliant with governance best practices due to 10b5-1 plan use and clear disclosure.

Use of a documented Rule 10b5-1 plan (adopted May 15, 2025) provides an affirmative defense against insider trading allegations, and the Form 4 discloses price range and weighted average sale price as required. The immediate sale of exercised shares is consistent with common executive liquidity management. The filing clearly states vesting schedule and option expiry, supporting transparency for shareholders and regulators.

Insider Feider Stephen
Role Chief Financial Officer
Sold 4,413 shs ($75K)
Approx. gross sale proceeds $75K
Approx. exercise cost $23K
Approx. pre-tax spread $53K
Type Security Shares Price Value
Exercise Employee Stock Option (right to buy) 4,413 $0.00 $0.00
Exercise Common Stock 4,413 $5.10 $23K
Sale Common Stock 4,413 $17.014 $75K
Holdings After Transaction: Employee Stock Option (right to buy) — 99,695 shares (Direct); Common Stock — 45,503 shares (Direct)
Footnotes (3)
  1. F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
  2. F2. The weighted average sale price for the transaction reported was $17.0140 and the range of prices were between $17.00 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  3. F3. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
Options exercised 4413.0000 shares Employee Stock Option exercised into Common Stock on August 22, 2025
Exercise price $5.1000 per share Conversion or exercise price of Employee Stock Option
Shares sold 4413.0000 shares Common Stock sale reported with transaction code S on August 22, 2025
Weighted average sale price $17.0140 per share Weighted average price; individual trades ranged between $17.00 and $17.12
Post-transaction common shares held 45,503 shares Direct Common Stock holdings after the reported transactions
Post-transaction options held 99,695.0000 shares Employee Stock Option position remaining after the 4,413-share exercise
Option vesting schedule 48 monthly installments Option vests in 48 equal monthly installments from September 14, 2023
Rule 10b5-1 Plan adoption date May 15, 2025 Plan governing the reported share sales
Rule 10b5-1 Plan regulatory
"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average sale price financial
"The weighted average sale price for the transaction reported was $17.0140."
Employee Stock Option financial
"Security title listed as Employee Stock Option (right to buy)."
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
vest in 48 equal monthly installments financial
"The shares subject to this option shall vest in 48 equal monthly installments."

FAQ

What insider transactions did BBNX CFO Stephen Feider report on August 22, 2025?
CFO Stephen Feider exercised options for 4,413 shares at $5.10 and sold 4,413 common shares at a weighted average price of $17.014, all dated August 22, 2025, as part of this reported insider activity.

How many Beta Bionics (BBNX) shares does the CFO hold after these Form 4 transactions?
After the reported trades, Stephen Feider directly holds 45,503 shares of common stock and employee stock options covering 99,695 shares, reflecting his remaining equity position following the August 22, 2025 exercise-and-sale sequence.

Was the BBNX CFO’s sale of 4,413 shares made under a Rule 10b5-1 plan?
Yes. The filing states the 4,413 shares were sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025, indicating the transactions followed a pre-arranged trading plan rather than being discretionary in timing.

What prices were involved in the BBNX CFO’s August 22, 2025 stock transactions?
The options were exercised at an exercise price of $5.10 per share, and the resulting 4,413 shares were sold at a weighted average price of $17.014 per share, with individual sale prices ranging between $17.00 and $17.12.

How do the BBNX CFO’s stock options vest according to the Form 4 footnotes?
The filing notes that the shares subject to the option vest in 48 equal monthly installments, measured from September 14, 2023, meaning the option grant vests gradually over four years rather than all at once.

What does the weighted average sale price mean in the BBNX CFO’s Form 4?
The weighted average sale price of $17.014 reflects multiple trades executed between $17.00 and $17.12. The company states that, upon request, it can provide the exact number of shares sold at each separate price to the SEC or any security holder.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Feider Stephen
(Last) (First) (Middle)
C/O BETA BIONICS, INC.
11 HUGHES
(Street)
IRVINE CA 92618
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/22/2025 M 4,413 A $5.1 49,916 D
Common Stock 08/22/2025 S(1) 4,413 D $17.014(2) 45,503 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $5.1 08/22/2025 M 4,413 (3) 09/13/2033 Common Stock 4,413 $0 99,695 D
Explanation of Responses:
1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
2. The weighted average sale price for the transaction reported was $17.0140 and the range of prices were between $17.00 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
/s/ Stephen Feider 08/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR